Table 3 Reported use of Montelukast (MK) as a subsequent or adjunctive therapy in eosinophilic gastroenteritis (EGE)
From: Successful use of montelukast in eosinophilic gastroenteritis: a case report and a literature review
Author(s) | Study design | Number of patients, gender (M%), mean age ± SD (years) | Affected segments | Medication(s) prior to starting MK, MK dose and duration (if known) | Outcomes | Follow up duration |
|---|---|---|---|---|---|---|
Adult cases | ||||||
Schwartz et al. [24] | Case report | One M, 27 | Small intestine | Prednisone 20 mg daily (induction for 4 weeks), Montelukast 10 mg daily, 20 months | Symptoms resolved | 20 months |
Muller et al. [22] | Prospective | Two, – 39.5 ± 19.5b | Stomach and small intestine | Prednisolone 40 m daily, Montelukast (dose/duration: not reported) | Symptoms resolved | 14 ± 5.6 months |
De Maeyer et al. [21] | Case report | One M, 38 | Duodenum | Methylprednisolone 16 mg daily (tapered to 4 mg) Montelukast 10 mg daily | Symptoms improved | Unknown |
Urek et al. [25] | Case report | One M, 18 | Serosal disease | Prednisolone 20 mg daily Montelukast 10 mg daily | Remission after 4 weeks of montelukast | Unknown |
Pediatric cases | ||||||
Lu and Ballas [23] | Retrospective | Two, M 50%, 17 and 39 | – | Prednisone 26–40 mg QOD Prednisone 30 mg daily | MK decreased prednisone requirement to 10 mg QOD in pediatric case | Unknown |
Quack et al. [20] | Case report | One F, 17 | Esophagus, stomach, ileum and colon | Prednisone 40 mg daily (tapered to 10 mg: relapsed) Montelukast 10 mg daily | Symptoms resolved | 24 months |
Menon et al. [26] | Case report | One F, 11 | Stomach and small bowel | Prednisolone (P): Relapsed after discontinuation Montelukast: Added to 5 mg P | Symptoms resolved | Unknown |
Vithayasai et al. [27] | Retrospectivea | One, – 6.75 ± 6.25b | – | Prednisolone (failed) Montelukast and ketotifen were started | No relapses | 3 months to 5 years |